Following

Dear Terri Purvis

Thank you for your reply, it is great, that journalists pay attention to that problem. 

But what do you think can we do, as a scientists?

Following

http://en.lug-info.com/news/one/four-ukrainian-army-servicemen-die-in-covid-19-vaccine-trial-21136

The vaccine, developed by Moscow's Gamaleya Institute, is known as "Gam-COVID-Vac". It is an adenovirus-based vaccine – as is the ChAdOx1 vaccine being tested by the University of Oxford – and entered a Phase I clinical trial back in June which recruited 38 healthy participants to evaluate its safety, tolerability and immunogenicity. According to the National Institutes of Health clinical trials study record, this trial is still ongoing.

However, the Russian media reported that Russian Health Minister Mikhail Murashko had declared on August 1 that "clinical trials of a coronavirus vaccine developed by the Gamaleya Center are over, paperwork is underway for the vaccine’s registration." To date, Russia has not published any scientific data regarding Gam-COVID-Vac.

Vaccine testing, manufacturing and approval is typically a lengthy and laborious processthat follows routine steps and can take between 10-15 years on average to complete. Clinical trials are critical for a vaccine's approval as they must demonstrate its safety, efficacy, help scientists to calculate what dosage is required to achieve immunization against a pathogen and to assess the best route of administration, number of boosters required at vaccination intervals and the duration of immunity. These trials are separated into phases, with Phase III data being required by the US Food and Drug Administration (FDA) for vaccine approval and dissemination.